Titan Short Term Investments vs Net Invested Capital Analysis

TTNP Stock

USD 6.34 0.21 3.21%

Titan Pharmaceuticals financial indicator trend analysis is much more than just breaking down Titan Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Titan Pharmaceuticals is a good investment. Please check the relationship between Titan Pharmaceuticals Short Term Investments and its Net Invested Capital accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.

Short Term Investments vs Net Invested Capital

Short Term Investments vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Titan Pharmaceuticals Short Term Investments account and Net Invested Capital. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Titan Pharmaceuticals' Short Term Investments and Net Invested Capital is 0.11. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Titan Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Titan Pharmaceuticals' Short Term Investments and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of Titan Pharmaceuticals are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Short Term Investments i.e., Titan Pharmaceuticals' Short Term Investments and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.11

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Short Term Investments

Short Term Investments is an item under the current assets section of Titan Pharmaceuticals balance sheet. It contains any investments Titan Pharmaceuticals undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Titan Pharmaceuticals can easily liquidate in the marketplace.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from Titan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Titan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.At this time, Titan Pharmaceuticals' Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 05/17/2024, Enterprise Value Over EBITDA is likely to grow to 0.0006, while Issuance Of Capital Stock is likely to drop slightly above 7.2 M.

Titan Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Other Current Assets	Property Plant And Equipment Gross	Common Stock	Common Stock Total Equity	Short Term Investments	Property Plant Equipment
Total Assets		0.59	-0.32	0.71	-0.11	0.69	-0.64	-0.02	0.74	0.95	0.08	-0.35	0.97	0.85	-0.47	0.45	-0.56	0.59	0.99	0.33	-0.33	0.09	0.7	0.66	-0.33	0.68
Short Long Term Debt Total	0.59		-0.35	0.68	-0.65	0.43	0.17	0.47	0.73	0.43	0.33	-0.17	0.46	0.66	-0.75	0.79	-0.86	0.82	0.54	0.69	0.17	-0.33	0.73	0.78	0.13	0.12
Other Current Liab	-0.32	-0.35		-0.2	0.2	0.09	0.13	0.12	-0.44	-0.36	0.3	0.15	-0.34	-0.5	-0.12	-0.36	0.32	-0.33	-0.36	-0.24	0.31	0.18	-0.48	-0.45	0.29	-0.15
Total Current Liabilities	0.71	0.68	-0.2		-0.62	0.65	-0.11	0.3	0.54	0.62	0.42	-0.21	0.64	0.58	-0.49	0.66	-0.58	0.85	0.65	0.44	0.11	0.16	0.48	0.52	0.09	0.55
Total Stockholder Equity	-0.11	-0.65	0.2	-0.62		-0.03	-0.61	-0.28	-0.25	-0.01	-0.17	0.31	-0.03	-0.18	0.3	-0.9	0.32	-0.87	-0.09	-0.22	-0.23	0.16	-0.15	-0.19	-0.19	0.15
Property Plant And Equipment Net	0.69	0.43	0.09	0.65	-0.03		-0.4	0.23	0.59	0.52	0.53	-0.1	0.56	0.54	-0.7	0.15	-0.49	0.36	0.61	0.34	0.01	0.36	0.45	0.46	0.0	0.8
Net Debt	-0.64	0.17	0.13	-0.11	-0.61	-0.4		0.39	-0.32	-0.73	0.2	0.16	-0.72	-0.48	-0.11	0.31	0.06	0.17	-0.67	0.04	0.54	-0.35	-0.36	-0.28	0.49	-0.66
Retained Earnings	-0.02	0.47	0.12	0.3	-0.28	0.23	0.39		0.12	-0.19	0.9	0.67	-0.17	0.02	-0.53	0.11	-0.58	0.2	-0.15	0.81	0.92	-0.24	0.1	0.27	0.92	-0.11
Accounts Payable	0.74	0.73	-0.44	0.54	-0.25	0.59	-0.32	0.12		0.58	0.11	-0.38	0.61	0.93	-0.58	0.52	-0.73	0.57	0.73	0.47	-0.24	-0.02	0.8	0.79	-0.24	0.44
Cash	0.95	0.43	-0.36	0.62	-0.01	0.52	-0.73	-0.19	0.58		-0.1	-0.36	0.99	0.75	-0.24	0.36	-0.42	0.49	0.97	0.21	-0.45	0.1	0.64	0.58	-0.44	0.64
Non Current Assets Total	0.08	0.33	0.3	0.42	-0.17	0.53	0.2	0.9	0.11	-0.1		0.6	-0.07	0.02	-0.57	-0.01	-0.46	0.16	-0.06	0.66	0.85	0.08	0.01	0.17	0.85	0.21
Non Currrent Assets Other	-0.35	-0.17	0.15	-0.21	0.31	-0.1	0.16	0.67	-0.38	-0.36	0.6		-0.36	-0.41	0.02	-0.51	-0.11	-0.44	-0.43	0.44	0.75	-0.04	-0.24	-0.1	0.77	-0.24
Cash And Short Term Investments	0.97	0.46	-0.34	0.64	-0.03	0.56	-0.72	-0.17	0.61	0.99	-0.07	-0.36		0.75	-0.29	0.37	-0.45	0.51	0.98	0.23	-0.44	0.11	0.66	0.6	-0.43	0.64
Net Receivables	0.85	0.66	-0.5	0.58	-0.18	0.54	-0.48	0.02	0.93	0.75	0.02	-0.41	0.75		-0.43	0.49	-0.63	0.57	0.85	0.41	-0.32	-0.05	0.76	0.72	-0.31	0.55
Common Stock Shares Outstanding	-0.47	-0.75	-0.12	-0.49	0.3	-0.7	-0.11	-0.53	-0.58	-0.24	-0.57	0.02	-0.29	-0.43		-0.39	0.73	-0.47	-0.38	-0.6	-0.28	0.26	-0.53	-0.6	-0.24	-0.22
Non Current Liabilities Total	0.45	0.79	-0.36	0.66	-0.9	0.15	0.31	0.11	0.52	0.36	-0.01	-0.51	0.37	0.49	-0.39		-0.44	0.95	0.45	0.22	-0.06	-0.21	0.41	0.4	-0.1	0.0
Other Stockholder Equity	-0.56	-0.86	0.32	-0.58	0.32	-0.49	0.06	-0.58	-0.73	-0.42	-0.46	-0.11	-0.45	-0.63	0.73	-0.44		-0.53	-0.49	-0.91	-0.24	0.23	-0.86	-0.94	-0.24	-0.18
Total Liab	0.59	0.82	-0.33	0.85	-0.87	0.36	0.17	0.2	0.57	0.49	0.16	-0.44	0.51	0.57	-0.47	0.95	-0.53		0.57	0.33	0.0	-0.08	0.48	0.48	-0.03	0.22
Total Current Assets	0.99	0.54	-0.36	0.65	-0.09	0.61	-0.67	-0.15	0.73	0.97	-0.06	-0.43	0.98	0.85	-0.38	0.45	-0.49	0.57		0.24	-0.45	0.07	0.7	0.64	-0.45	0.65
Short Term Debt	0.33	0.69	-0.24	0.44	-0.22	0.34	0.04	0.81	0.47	0.21	0.66	0.44	0.23	0.41	-0.6	0.22	-0.91	0.33	0.24		0.55	-0.3	0.63	0.76	0.57	0.07
Other Current Assets	-0.33	0.17	0.31	0.11	-0.23	0.01	0.54	0.92	-0.24	-0.45	0.85	0.75	-0.44	-0.32	-0.28	-0.06	-0.24	0.0	-0.45	0.55		-0.17	-0.27	-0.1	1.0	-0.26
Property Plant And Equipment Gross	0.09	-0.33	0.18	0.16	0.16	0.36	-0.35	-0.24	-0.02	0.1	0.08	-0.04	0.11	-0.05	0.26	-0.21	0.23	-0.08	0.07	-0.3	-0.17		-0.14	-0.17	-0.15	0.46
Common Stock	0.7	0.73	-0.48	0.48	-0.15	0.45	-0.36	0.1	0.8	0.64	0.01	-0.24	0.66	0.76	-0.53	0.41	-0.86	0.48	0.7	0.63	-0.27	-0.14		0.98	-0.26	0.3
Common Stock Total Equity	0.66	0.78	-0.45	0.52	-0.19	0.46	-0.28	0.27	0.79	0.58	0.17	-0.1	0.6	0.72	-0.6	0.4	-0.94	0.48	0.64	0.76	-0.1	-0.17	0.98		-0.08	0.26
Short Term Investments	-0.33	0.13	0.29	0.09	-0.19	0.0	0.49	0.92	-0.24	-0.44	0.85	0.77	-0.43	-0.31	-0.24	-0.1	-0.24	-0.03	-0.45	0.57	1.0	-0.15	-0.26	-0.08		-0.24
Property Plant Equipment	0.68	0.12	-0.15	0.55	0.15	0.8	-0.66	-0.11	0.44	0.64	0.21	-0.24	0.64	0.55	-0.22	0.0	-0.18	0.22	0.65	0.07	-0.26	0.46	0.3	0.26	-0.24

Click cells to compare fundamentals

Titan Pharmaceuticals Account Relationship Matchups

Titan Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.5M	8.1M	8.0M	4.1M	8.1M	7.7M
Short Long Term Debt Total	4.4M	809K	299K	187K	565K	536.8K
Other Current Liab	1.9M	2.0M	1.5M	1.6M	519K	493.1K
Total Current Liabilities	3.6M	4.2M	2.7M	2.6M	1.4M	1.4M
Total Stockholder Equity	1.4M	3.5M	5.1M	1.4M	6.6M	6.3M
Property Plant And Equipment Net	1.2M	759K	717K	407K	68K	64.6K
Net Debt	(782K)	(4.6M)	(5.7M)	(2.8M)	(6.2M)	(6.5M)
Retained Earnings	(349.0M)	(367.3M)	(376.1M)	(386.3M)	(391.8M)	(372.2M)
Accounts Payable	1.4M	1.3M	795K	695K	348K	330.6K
Cash	5.2M	5.4M	6.0M	2.9M	6.8M	8.3M
Non Current Assets Total	1.2M	759K	765K	455K	68.0K	64.6K
Non Currrent Assets Other	794K	(1.2M)	(759K)	48K	(1.0)	(0.95)
Cash And Short Term Investments	5.2M	5.4M	6.0M	2.9M	6.8M	6.4M
Net Receivables	993K	884K	112K	36K	1.0M	1.6M
Common Stock Shares Outstanding	1.3K	188.7K	486.5K	671.7K	752K	789.6K
Liabilities And Stockholders Equity	9.5M	8.1M	8.0M	4.1M	8.1M	7.7M
Non Current Liabilities Total	3.8M	4.5M	332K	187K	65K	0.0
Other Stockholder Equity	350.4M	370.8M	381.2M	387.6M	398.5M	418.4M
Total Liab	8.1M	4.6M	2.9M	2.7M	1.4M	1.4M
Total Current Assets	8.3M	7.3M	7.2M	3.6M	8.0M	7.6M
Short Term Debt	272K	477K	112K	122K	565K	1.1M
Other Current Assets	1.1M	522K	480K	314K	199K	189.1K
Property Plant And Equipment Gross	1.2M	618K	2.1M	2M	774K	883.3K
Common Stock	57K	7K	10K	15K	1K	950.0
Property Plant Equipment	794K	1.2M	759K	717K	824.6K	826.4K
Long Term Debt	3.6M	3.8M	4.0M	332K	298.8K	283.9K
Retained Earnings Total Equity	(323.3M)	(332.6M)	(349.0M)	(367.3M)	(330.6M)	(347.1M)
Net Tangible Assets	6.8M	1.4M	3.5M	5.1M	4.6M	4.7M
Capital Surpluse	26.3M	339.4M	350.4M	370.8M	426.4M	447.7M
Net Invested Capital	5.5M	4.2M	5.1M	1.4M	7.1M	4.8M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:

How To Invest In Titan

Details

Is Titan Stock a good investment?

Details

What is Titan Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Titan Stock analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets

Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(7.41)

Revenue Per Share

0.245

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.75)

Return On Equity

(1.39)

The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Titan Short Term Investments vs Net Invested Capital Analysis

Short Term Investments vs Net Invested Capital

Short Term Investments vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Short Term Investments

Net Invested Capital

Titan Pharmaceuticals fundamental ratios Correlations

Titan Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Titan Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Titan Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Investments	+ 1.0	Other Current Assets
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.98	Cash And Short Term Investments
Common Stock Total Equity	+ 0.98	Common Stock
Cash And Short Term Investments	+ 0.97	Total Assets

Common Stock Total Equity	- 0.94	Other Stockholder Equity
Short Term Debt	- 0.91	Other Stockholder Equity
Non Current Liabilities Total	- 0.9	Total Stockholder Equity
Total Liab	- 0.87	Total Stockholder Equity
Common Stock	- 0.86	Other Stockholder Equity
Other Stockholder Equity	- 0.86	Short Long Term Debt Total